<DOC>
	<DOC>NCT00102817</DOC>
	<brief_summary>This trial is conducted in the United States of America (USA). This is a 12 month study to determine if Norditropin is safe and effective in children with IGF deficiency.</brief_summary>
	<brief_title>Somatropin (Norditropin) in Insulin-like Growth Factor (IGF) Deficient Children</brief_title>
	<detailed_description />
	<mesh_term>Dwarfism</mesh_term>
	<mesh_term>Dwarfism, Pituitary</mesh_term>
	<criteria>Ages 315 Presence of growth failure indicated by height standard deviation score less than equal to 2 Body mass index greater than or equal to 25th percentile for height age IGF concentration less than or equal to 33rd percentile</criteria>
	<gender>All</gender>
	<minimum_age>3 Years</minimum_age>
	<maximum_age>13 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Growth Hormone Disorder</keyword>
</DOC>